Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZE3GK)

Drug Name

PF-06865571 Drug Info

Synonyms

Ervogastat; Ervogastat [INN]; 2186700-33-2; BSOIY5AKQW; PF-06865571; UNII-BSOIY5AKQW; 2-(5-((3-Ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-((3S)-oxolan3-yl)pyrimidine-5-carboxamide; 5-Pyrimidinecarboxamide, 2-(5-((3-ethoxy-2-pyridinyl)oxy)-3-pyridinyl)-N-((3S)-tetrahydro-3-furanyl)-; CHEMBL4760665; SCHEMBL19875384; GTPL12241; US10071992, Example 1; BDBM276750; EX-A7128; US10071992, Example 3.4; AKOS040759712; AT28030; compound 6 [PMID: 34635855]; PF06865571; 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide; (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 134262752
TTD Drug ID: DMZE3GK

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Diacylglycerol O-acyltransferase 2 (DGAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B3	DMQVRZH	Chronic renal failure	GB61.Z	Approved	[3]
ARI-3037MO	DM9LNXS	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
PF-06427878	DMGB32Z	Cardiovascular disease	BA00-BE2Z	Phase 1	[5]
PMID25470667-Compound-Figure4-1A	DMMVQW8	N. A.	N. A.	Patented	[6]
PMID25470667-Compound-roselipins	DMCF2G7	N. A.	N. A.	Patented	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Diacylglycerol O-acyltransferase 2 (DGAT2)	TTRHEQ4	DGAT2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04321031) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3. U.S.National Institutes of Health.
2	Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. J Med Chem. 2022 Nov 24;65(22):15000-15013.
3	Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
4	2011 Pipeline of Arisaph Pharmaceuticals.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.